139 related articles for article (PubMed ID: 27666826)
1. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.
Nissinen TA; Degerman J; Räsänen M; Poikonen AR; Koskinen S; Mervaala E; Pasternack A; Ritvos O; Kivelä R; Hulmi JJ
Sci Rep; 2016 Sep; 6():32695. PubMed ID: 27666826
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of activin receptor 2 signalling ameliorates metabolic dysfunction-associated steatotic liver disease in western diet/L-NAME induced cardiometabolic disease.
Swan J; Szabó Z; Peters J; Kummu O; Kemppi A; Rahtu-Korpela L; Konzack A; Hakkola J; Pasternack A; Ritvos O; Kerkelä R; Magga J
Biomed Pharmacother; 2024 Jun; 175():116683. PubMed ID: 38705130
[TBL] [Abstract][Full Text] [Related]
3. New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration.
Pasteuning-Vuhman S; Boertje-van der Meulen JW; van Putten M; Overzier M; Ten Dijke P; Kiełbasa SM; Arindrarto W; Wolterbeek R; Lezhnina KV; Ozerov IV; Aliper AM; Hoogaars WM; Aartsma-Rus A; Loomans CJ
FASEB J; 2017 Jan; 31(1):238-255. PubMed ID: 27733450
[TBL] [Abstract][Full Text] [Related]
4. INVITED REVIEW: Inhibitors of myostatin as methods of enhancing muscle growth and development.
Chen PR; Lee K
J Anim Sci; 2016 Aug; 94(8):3125-3134. PubMed ID: 27695802
[TBL] [Abstract][Full Text] [Related]
5. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy.
Singh P; Rong H; Gordi T; Bosley J; Bhattacharya I
Clin Transl Sci; 2016 Dec; 9(6):302-310. PubMed ID: 27700008
[TBL] [Abstract][Full Text] [Related]
6. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
7. S6K1 Is Required for Increasing Skeletal Muscle Force during Hypertrophy.
Marabita M; Baraldo M; Solagna F; Ceelen JJM; Sartori R; Nolte H; Nemazanyy I; Pyronnet S; Kruger M; Pende M; Blaauw B
Cell Rep; 2016 Oct; 17(2):501-513. PubMed ID: 27705797
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial ROS regulate oxidative damage and mitophagy but not age-related muscle fiber atrophy.
Sakellariou GK; Pearson T; Lightfoot AP; Nye GA; Wells N; Giakoumaki II; Vasilaki A; Griffiths RD; Jackson MJ; McArdle A
Sci Rep; 2016 Sep; 6():33944. PubMed ID: 27681159
[TBL] [Abstract][Full Text] [Related]
9. Mechanosensing in Myosin Filament Solves a 60 Years Old Conflict in Skeletal Muscle Modeling between High Power Output and Slow Rise in Tension.
Marcucci L; Reggiani C
Front Physiol; 2016; 7():427. PubMed ID: 27721796
[TBL] [Abstract][Full Text] [Related]
10. The problem Of muscle hypertrophy: Revisited.
Buckner SL; Dankel SJ; Mattocks KT; Jessee MB; Mouser JG; Counts BR; Loenneke JP
Muscle Nerve; 2016 Dec; 54(6):1012-1014. PubMed ID: 27717161
[TBL] [Abstract][Full Text] [Related]
11. MyoD Regulates Skeletal Muscle Oxidative Metabolism Cooperatively with Alternative NF-κB.
Shintaku J; Peterson JM; Talbert EE; Gu JM; Ladner KJ; Williams DR; Mousavi K; Wang R; Sartorelli V; Guttridge DC
Cell Rep; 2016 Oct; 17(2):514-526. PubMed ID: 27705798
[TBL] [Abstract][Full Text] [Related]
12. Protein Supplementation Does Not Significantly Augment the Effects of Resistance Exercise Training in Older Adults: A Systematic Review.
Thomas DK; Quinn MA; Saunders DH; Greig CA
J Am Med Dir Assoc; 2016 Oct; 17(10):959.e1-9. PubMed ID: 27670605
[TBL] [Abstract][Full Text] [Related]
13. Signaling Pathways That Control Muscle Mass.
Vainshtein A; Sandri M
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635462
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle.
Montalvo RN; Doerr V; Min K; Szeto HH; Smuder AJ
Am J Physiol Regul Integr Comp Physiol; 2020 Feb; 318(2):R227-R233. PubMed ID: 31774307
[TBL] [Abstract][Full Text] [Related]
15. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenia: Aging-Related Loss of Muscle Mass and Function.
Larsson L; Degens H; Li M; Salviati L; Lee YI; Thompson W; Kirkland JL; Sandri M
Physiol Rev; 2019 Jan; 99(1):427-511. PubMed ID: 30427277
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia.
Damrauer JS; Stadler ME; Acharyya S; Baldwin AS; Couch ME; Guttridge DC
Eur J Transl Myol; 2018 Apr; 28(2):7590. PubMed ID: 29991992
[TBL] [Abstract][Full Text] [Related]
18. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss.
Johns N; Stretch C; Tan BH; Solheim TS; Sørhaug S; Stephens NA; Gioulbasanis I; Skipworth RJ; Deans DA; Vigano A; Ross JA; Bathe OF; Tremblay ML; Kaasa S; Strasser F; Gagnon B; Baracos VE; Damaraju S; Fearon KC
J Cachexia Sarcopenia Muscle; 2017 Feb; 8(1):122-130. PubMed ID: 27897403
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice.
Cella PS; Matos RLN; Marinello PC; Costa JCD; Moura FA; Bracarense APFRL; Chimin P; Deminice R
PLoS One; 2024; 19(4):e0301379. PubMed ID: 38648220
[TBL] [Abstract][Full Text] [Related]
20. Formoterol reduces muscle wasting in mice undergoing doxorubicin chemotherapy.
de Lima Junior EA; Teixeira AAS; Silveira LS; Jové Q; Ladrón NÁ; Pereira MG; López-Soriano FJ; Argilés JM; Brum PC; Busquets S; Neto JCR
Front Oncol; 2023; 13():1237709. PubMed ID: 38234397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
